ABL1 and leukemia: Our study suggests that tamoxifen targets PRKCI that encodes a member of the protein kinase C (PKC) family of serine/threonine protein kinases and is found to be necessary for BCR-ABL-mediated resistance to drug-induced apoptosis and therefore protects leukemia cells against drug-induced apoptosis [36].